Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Schell

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Journal of Clinical Virology Plus|September 1, 2023
SARS-CoV-2 antibody response duration and neutralization following natural infectionChristopher W Dukes, Renata Am Rossetti, Jonathan A Hensel, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
The Lancet. Oncology|December 21, 2016
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based studyJacob G Scott, Anders Berglund, Michael J Schell, et al.
Vaccine|July 3, 2025
Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201Anna R Giuliano, Anna Beltrame, Luisa L Villa, et al.
The Journal of Infection|May 3, 2026
Genotype Distribution of Human Papillomavirus (HPV) Types in Oral Gargle Specimens among Men Living with HIV in Mexico, Brazil, and Puerto Rico: a Cross-Sectional StudyAnna Beltrame, Anna R Giuliano, Luisa L Villa, et al.
Oncoimmunology|March 25, 2021
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapseYasmin Kamal, Dennis Dwan, Hannah J Hoehn, et al.
Cancers|April 3, 2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II StudyChristine H Chung, Marcelo Bonomi, Conor E Steuer, et al.
Scientific Reports|May 29, 2026
Alcohol consumption and oral human papillomavirus infection among men living with HIV: a cross-sectional study from the ULACNet 201 trialAnna Beltrame, Luisa L Villa, Eduardo Lazcano-Ponce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaChristine H Chung, Jiannong Li, Conor E Steuer, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Journal of Clinical Virology Plus|September 1, 2023
SARS-CoV-2 antibody response duration and neutralization following natural infectionChristopher W Dukes, Renata Am Rossetti, Jonathan A Hensel, et al.
Nature Communications|May 25, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trialJeffrey S Johnson, Justin W Miller, Firas Hatoum, et al.
The Lancet. Oncology|December 21, 2016
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based studyJacob G Scott, Anders Berglund, Michael J Schell, et al.
Vaccine|July 3, 2025
Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201Anna R Giuliano, Anna Beltrame, Luisa L Villa, et al.
The Journal of Infection|May 3, 2026
Genotype Distribution of Human Papillomavirus (HPV) Types in Oral Gargle Specimens among Men Living with HIV in Mexico, Brazil, and Puerto Rico: a Cross-Sectional StudyAnna Beltrame, Anna R Giuliano, Luisa L Villa, et al.
Oncoimmunology|March 25, 2021
Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapseYasmin Kamal, Dennis Dwan, Hannah J Hoehn, et al.
Cancers|April 3, 2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II StudyChristine H Chung, Marcelo Bonomi, Conor E Steuer, et al.
Scientific Reports|May 29, 2026
Alcohol consumption and oral human papillomavirus infection among men living with HIV: a cross-sectional study from the ULACNet 201 trialAnna Beltrame, Luisa L Villa, Eduardo Lazcano-Ponce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaChristine H Chung, Jiannong Li, Conor E Steuer, et al.
Pageof 16